Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | MM: AMG 701 BiTE

Yu-Tzu Tai • 15 Sep 2019
IMW 2019
Multiple Myeloma Antibodies

Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA, speaks on recent research which indicates the success of AMG 701, a new Bi-specific T-cell engager (BiTE) both in monotherapy and combination therapy when tackling tumor cells directly. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Yu-Tzu Tai

Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
3:28
Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma
5:22
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
1:35
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
Reducing CAR-T toxicity
3:09
Reducing CAR-T toxicity
Yu-Tzu Tai • 15 Sep 2019

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Yu-Tzu Tai • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Yu-Tzu Tai • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Yu-Tzu Tai • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Yu-Tzu Tai • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals